MedTrace Logo

Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.

NCT03458923 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-03-08

No results posted yet for this study

Summary

The study aims to compare the effect of intravitreal non steroidal anti inflammatory (Diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti vascular endothelial growth factor (Ranibizumab), measuring central macular thickness changes and best corrected visual acuity.

Conditions

Interventions

DRUG

Diclofenac Sodium 0.1 ml containing 500µg

15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months

DRUG

Ranibizumab 0.5 mg Solution for Injection

15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mohamed S El Agha, PhD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458923 on ClinicalTrials.gov